Houston xenograft production facility opens

United Therapeutics opened its third Designated Pathogen-Free facility in Houston to manufacture investigational xenokidneys and xenohearts for clinical development and potential commercial production after regulatory approval.

The biosecure Houston site expands United Therapeutics' U.S. organ-manufacturing network alongside facilities in Virginia and Minnesota. The company says the Houston and Minnesota sites are designed to support scaled commercial xeno-organ production if the investigational products receive approval.

Headline metrics

U.S. DPF facilities	3	Houston is United Therapeutics' third Designated Pathogen-Free xenograft production facility.
Investigational product families	3	UKidney, UThymoKidney, and UHeart are named in the company release.

Highlights

Purpose-built productionThe Houston facility is designed to manufacture xenokidneys and xenohearts in a tightly controlled biosecure environment.
Commercial-scale pathwayUnited Therapeutics says the Houston and Stewartville facilities are designed to enable scaled commercial production following product approval.
Domestic networkThe opening adds a Texas site to existing U.S. facilities in Christiansburg, Virginia, and Stewartville, Minnesota.

Resources

Company-issued announcementbusinesswire.com
United Therapeutics investor relationsir.unither.com